RT Journal Article
SR Electronic
T1 Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients with Long-Term Indication for Anticoagulation: Systematic Review and Meta-Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.22.20198119
DO 10.1101/2020.09.22.20198119
A1 Costa, Gonçalo
A1 Sousa, José Pedro
A1 Gonçalves, Lino
A1 Teixeira, Rogério
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.22.20198119.abstract
AB Objective The aim of this study was to compare antithrombotic regimens following transcatheter aortic valve implantation (TAVI) in patients requiring long-term oral anticoagulation (OAC).Methods We systematically searched PubMed, Embase, and Cochrane databases for interventional and observational studies comparing OAC to OAC plus single antiplatelet therapy (SAPT).Results Five studies were included (four registry-based and one randomized controlled trial), comprising a total of 1318 patients. Our meta-analysis revealed lower rates of severe bleeding (pooled odds ratio [OR] 0.46 [0.31, 0.69], P<0.01, I2=0%) and major bleeding (pooled OR 0.46 [0.27,0.79], P<0.01, I2=0%) for the OAC group than for the OAC-plus-SAPT group. There was a nonsignificant trend towards reduced life-threatening bleeding events in the OAC group (pooled OR 0.54 [0.27,1.08], P=0.08, I2=11%). There was no difference between groups in the risks of stroke (pooled OR 1.02 [0.58,1.80], P=0.58, I2= 0%) or all-cause mortality (pooled OR 1.04 [0.75,1.42], P=0.83, I2= 0%) after TAVI.Conclusions Our pooled analysis suggests that for patients with an indication for long-term OAC after TAVI, double anti-thrombotic therapy, compared to OAC alone, increased the risk of bleeding without reducing cerebrovascular events and all-cause mortality.Key questionsWhat is already known about this subject?Transcatheter Aortic Valve Implantation (TAVI) is a landmark techinique in interventional cardiology with growing clinical experience and continuous refinement of procedural techniques and devices. Nevertheless, the post-TAVI antithrombotic regimen guidelines are largely based on expert opinions and followed variably across the globe.What does this study add?Our pooled analysis suggests that for patients with an indication for long-term anticoagulation after TAVI, double anti-thrombotic therapy, compared to OAC alone, increased the risk of bleeding without reducing cerebrovascular events and all-cause mortality.How might this impact on clinical practice?Our finding may prove insightful for future recommendations regarding the conundrum of the best antithrombotic strategy, particularly for patients with AF.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors have no conflictics of interest to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PRISMAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred in the manuscript is available to the general publicAFAtrial FibrillationASAortic StenosisCADCoronary Artery DiseaseHTNHypertensionMIMyocardial InfarctionNRNon-ReportedOACOral AnticoagulationPADPeripheral Artery DiseasePRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesPCIPercutaneous Coronary InterventionRCTRandomized Controlled TrialSAPTSingle Antiplatelet TherapyTAVITranscatheter Aortic-Valve ImplantationVARC-2Valve Academic Research Consortium-2VKAVitamin K Antagonist